SS Innovations International Inc. (NASDAQ: SSII), a developer of innovative surgical robotic technologies, announced record second-quarter revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period last year. This growth signals continued momentum for the company’s SSi Mantra surgical robotic platform, as installations and cumulative procedures expand across global markets. First-half revenue reached $25.0 million, up 65.6% from $15.1 million in the first half of 2025, reflecting accelerating adoption.
The company’s gross profit for the second quarter increased 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% in the year-earlier quarter (https://nnw.fm/zxrT1). For the first half, gross profit improved 77.5% to $12.4 million, with gross margin showing improvement. These financial results underscore the company’s ability to scale its operations while managing costs, despite the margin dip attributed to product mix and investments in expansion.
SS Innovations saw its SSi Mantra installations rise 30.4% to 30 systems during the quarter, bringing the installed base to 224 systems across 12 countries. Cumulative surgeries performed on the platform reached 12,272, demonstrating growing clinical acceptance and utilization. The company’s telesurgery achievements are extending the clinical profile of SSi Mantra, highlighting its potential to bring robotic surgery to underserved regions. However, system installations remain the primary commercial growth driver, and the company continues to focus on expanding its global footprint.
Looking ahead, U.S. and European regulatory milestones could serve as important catalysts for SS Innovations. The company is targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. Achieving these milestones would open access to two of the world’s largest healthcare markets, potentially accelerating revenue growth and solidifying SSi Mantra’s position in the competitive surgical robotics landscape. The company’s progress in telesurgery, which allows surgeons to operate remotely, also differentiates it from competitors and aligns with broader trends toward telemedicine and minimally invasive procedures.
The strong financial performance and strategic advancements come as the global surgical robotics market is projected to grow significantly, driven by demand for precision, reduced recovery times, and improved patient outcomes. SS Innovations’ focus on affordability and versatility, particularly in emerging markets, positions it to capture a share of this growth. With a robust installed base and a pipeline of regulatory approvals, the company is poised to leverage its momentum and deliver value to shareholders.
Investors should note that the latest news and updates relating to SSII are available in the company’s newsroom at https://nnw.fm/SSII. As the company advances its regulatory timeline and expands its commercial operations, its ability to maintain growth while managing margins will be key to long-term success.
